Introduction
Apolipoprotein C-Ill is a major protein constituent of triglyceride rich lipoproteins and HDL. It occurs in plasma in three isoforms differing by their sialic acid content. Apo C-III putatively inhibits lipolysis and the apo E mediated hepatic uptake of remnants from triglyceride rich particles. We identified a heterozygous carrier of an apolipoprotein C-III variant by the presence of additional bands after isoelectric focusing (IEF) of VLDL. Structural analysis of the variant protein by HPLC, time-of-flight secondary ion mass spectrometry, and automated gas phase sequencing revealed a lysine to glutamic acid replacement in position 58. The underlying A to G exchange was verified by direct sequencing subsequent to amplification by polymerase chain reaction of exon 4 of the apo C-III gene. Family studies revealed vertical transmission of this defect.
The two variant carriers exhibited plasma concentrations of HDL cholesterol and apo A-I above the 95th percentiles of sex matched controls whereas the unaffected father and sister showed normal values. The plasma concentrations of apo C-III in the two variant carriers were decreased by 30-40% compared with those of the two unaffected family members and to random controls. Using two-dimensional immunoelectrophoresis as well as IEF and subsequent scanning densitometry, we found that the low serum concentration of apo C-III was a consequence of diminished concentrations of the variant apo C-III isoproteins in both VLDL (15% of normal) and HDL (25% of normal). Apo C-III(Lys58 -Glu) heterozygotes possessed un- usual HDL as demonstrated by nondenaturing gradient gel electrophoresis. They consisted mainly of HDL2b and contained a proportion of atypically large particles, enriched in apo E, with a Stokes diameter of 13-18 nm and resembling HDLC.
In conclusion, heterozygosity for a structural apo C-Ill variant -apo C-III(Lys58--Glu)-was identified in two hyperalphalipoproteinemic subjects characterized by the presence of low plasma apo C-III concentrations and atypically large HDL. (J. Clin. Invest. 1991. 87:1724-1731.) Key words: triglyceride rich particles * HDL subclasses -lipolysis -time-of-flight secondary ion mass spectrometry * gradient gel electrophoresis Several prospective epidemiological studies revealed an inverse correlation between the plasma concentration of HDL cholesterol and the risk ofcoronary heart disease (reviewed in 1). The variation of HDL cholesterol levels in the population is determined by environmental as well as by genetic factors. Family and twin studies have estimated the impact of genes to be -50% (2) . Efforts undertaken to unravel the gene loci influencing the plasma concentration of HDL cholesterol have focused on APOLP 1, as this locus codes for the apolipoproteins A-I, C-IlI, and A-IV, all ofwhich are involved in the formation and metabolism ofHDL (3) (4) (5) . Whereas some mutations in the apo A-I gene have been shown to be associated with familial HDL deficiency (6) , little is known about the effects of mutations in the genes for apo C-Ill and apo A-IV on HDL cholesterol plasma concentration.
Apo C-Ill, a protein consisting of 79 amino acids of known sequence (7) (8) (9) (10) , is found predominantly in VLDL and in HDL (11) . Isoelectric focusing (IEF)' separates apo C-III into three isoforms that differ in their degree of 0-linked sialyation at the threonine residue in position 74: apo C-III0 (no sialic acid), apo C-III1 (1 mol sialic acid) and apo C-II2 (2 mol sialic acid) (12) (13) (14) (15) . The physiological function ofapo C-III is not yet fully understood. In vitro, high concentrations of apo C-III have been shown to inhibit lipoprotein lipase (LPL) (16, 17) and hepatic triglyceride lipase (18) , enzymes responsible for the clearance of triglyceride rich particles from the plasma. In contrast to normal plasma, apo A-I/apo C-III deficient plasma is not able to inhibit LPL activity, thus supporting the hypothesis that apo C-III also inhibits LPL in vivo (19) . Furthermore, apo C-III was shown to inhibit the hepatic uptake of triglyceride rich particles (20) (21) (22) . Apo C-III also appears to interfere with HDL receptor mediated uptake of lipoproteins; apo C-III containing proteoliposomes were shown to compete for the specific binding of HDL and of apo A-I proteoliposomes to cell surface receptors of various rat cells (23) (24) (25) .
Previously, two genetic variants of apo C-Ill have been detected on the basis of additional bands after IEF: One variant was characterized by the presence of a fourth anodic band, which was shown to be due to oversialyation of the protein (14) . In the other apo C-Ill variant, the substitution of threonine in position 74 by alanine prevented O-glycosylation (26) (27) (28) . Both apo C-III variants were not found associated with any dyslipoproteinemic phenotype. Two cases of familial apo C-III deficiency that were characterized by increased prevalence of precocious coronary heart disease were also deficient in apo A-I. Therefore, the potential role of apo C-Ill in the pathogenesis of premature atherosclerosis in these families remained undefined (29) (30) (31) (32) (38) . Calibration was done with a purified apo C-Ill of known protein concentration (39) Neville (43) .
Immunoelectrophoresis was performed in a 1% agarose gel containing 8% antiserum against apo C-Ill (42) . After (45, 46) . After a 24-h run at 40,000 rpm, the sample was portioned into fractions of 500 Ml using a fraction collector and a peristaltic pump (Pharmacia-LK-B Instruments Inc., Bromma, Sweden). Concentrations of total and free cholesterol, triglycerides, phosphatidylcholine, sphingomyeline, and apo A-I were determined as described above. 50,Ml of each fraction was analyzed by nondenaturing polyacrylamide gradient electrophoresis (see below) as well as by IEF and subsequent immunoblotting (see above).
Gradient gel electrophoresis. Nondenaturing polyacrylamide gradient gel electrophoresis of undelipidated HDL (1.069 < 1.21 g/ml) or of fractions obtained by density gradient ultracentrifugation was performed principally as described by Nichols et al. (47) but using labmade gels of 1.5-mm thickness and a buffer system described by Altland et al. (48) . Either 40 Ml HDL emulsion or 50 Mul of the fractions obtained by density gradient ultracentrifugation were applied to polyacrylamide gradient gels ranging from S to 30% or from 5 to 21% (wt/ vol), respectively. Electrophoresis was interrupted when the bromphenol blue front had left the gel.
Densitometry. The relative distribution of the apo C-Ill isoproteins and the size distribution of HDL particles were analyzed by densitometry of Coomassie blue stained gels subsequent to isoelectric focusing of apo VLDL and apo HDL or subsequent to nondenaturing gradient gel electrophoresis, respectively. Scanning densitometry was performed with Ultrascan (LKB Instruments Inc., Bromma, Sweden). Peak areas reflecting the intensity of the apo C-Ill bands and thus the concentration of specific isoproteins were integrated automatically with SP 4270 (Spectra-Physics Inc., Mountain View, CA). The Stokes diameters of the HDL particles were determined as described by Nichols et al. (47) .
Isolation and structural analysis ofapo C-Ill isoproteins. Isolation and structural analysis ofthe apo C-Ill variant was done by a procedure that has been described by our laboratory previously (14, 49, 50). Briefly, VLDL apolipoproteins isolated from 11I plasma by ultracentrifugation and subsequent delipidation were separated by isoelectric focusing in pH 3.75 to pH 5.25 . The gels were rehydrated with 6 M urea and 15% glycerol (wt/vol). Separation was performed overnight at 2,000 V, 15 mA, and 5 W, and for 4 further h at 3,000 V. For band localization, a 1-cm wide gel strip was removed from one side ofthe gel and stained with Coomassie blue. By referring to the bands in the stained gels, gel strips containing the normal and the variant apo C-Ill isoforms were cut out of the remaining unstained gel. After min, the acetonitrile content of the gradient was increased to 50% within 50min and to 100% during the following 2 min. A peak detector monitoring at 215 nm and a fraction collector (Pharmacia-LK-B) were used to collect the peptides separately. HPLC fractions were analyzed by time-of-flight secondary ion mass spectrometry (TOF-SIMS) (49). Mass differences between peptides, of normal apo C-Ill that were lost from the chromatogram, and peptides of variant apo C-Ill that were newly generated, were used to calculate possible amino acid substitutions. The predicted amino acid substitution was confirmed by sequence analysis of the affected tryptic peptide. Sequence analysis was performed by automated gas phase protein sequencing (Applied Biosystems, Inc., Foster City, CA).
Verification of the mutation by direct sequencing of the apo C-III gene. Genomic DNA was isolated from leucocytes of four family members. Exon 4 of the apo C-III gene with its flanking regions was selectively amplified by the polymerase chain reaction (PCR) (51) using 5'-TCGTCCAGTGGGGACATGGGTGTGG-3' as the 5'-primer and 5'-ACCTGGAGTCTGTCCAGTGCCCACC-3' as the 3'-primer. 30 cycles of PCR were done as described by the supplier of the Taq polymerase (Cetus Corp., Emeryville, CA) except that (a) initial denaturation was done at 960C for 90 s; (b) annealing was done at 620C for 60 s; and (c) extension was done at 70'C for 60 s. The product was purified by electrophoresis in a 2.5% Nusieve agarose/1% agarose gel (wt/vol) (FMC Corp., Rockland, ME). PCR fragments of expected size were cut out of the gel and electroeluted in 0.5X TAE (0.04 M Tris acetate, 0.001 M EDTA, pH 8.0) for 1.5 h at 180 V. DNA was desalted and concentrated to 70 Al by ultrafiltration centrifugation in Centricon X-100 tubes as recommended by the supplier (Amicon Corp., Danvers, MA). Single strand DNA was produced from the purified double strand DNA by the method of Gyllenstein and Erlich (52) using the same reaction and purification parameters as above. A second primer was not used. After reduction of the sample volume to 10 ,ul in an evaporation centrifuge, the sequencing reaction was done directly using T7 polymerase (Pharmacia-LKB) and the above-described 5'-primer as a sequencing primer. Electrophoresis was performed in a 6% polyacrylamide gel (29:1 acrylamide:bisacrylamide), 135 mM Tris, 45 mM boric acid, and 2.5 mM EDTA. Films were exposed overnight. 
Results
Description of the apo C-III variant. During a study of apo E polymorphism in 200 students by IEF of VLDL apolipoproteins, a sample of a 27-yr old woman (P.Sch.) was found to exhibit two additional bands localized anodic from normal apo C-Ill2 (Fig. 1 a) . Two-dimensional SDS electrophoresis revealed that the two bands exhibited a molecular weight identical to that of apo C-Ill (Fig. 1 b) . Both bands were shown to be apo C-Ill immunoreactive by immunoblotting of the proband's plasma subsequent to IEF (Fig. 1 c) and by two-dimensional immunoelectrophoresis of the proband's apo VLDL (Fig. 2) . IEF performed subsequently to treatment of VLDL with neuraminidase made the additional abnormal bands disappear and generated a new band that was in a pI position slightly anodic from normal apo C-III,. This band was assumed to contain the desialyated apo C-Ill variant. In native (i.e., untreated with neuraminidase) serum, apo VLDL, and apo HDL this apo C-Ill0 variant was detectable neither by IEF and subsequent immunoblotting (Fig. 1 c) nor by two-dimensional immunoelectrophoresis (Fig. 2) .
After IEF of apo VLDL and subsequent protein staining as well as by IEF of whole plasma and subsequent immunoblotting, the relative concentration of the variant apo C-Ill isoforms appeared to be markedly lower than that of normal apo C-III. This observation was confirmed both by two-dimensional immunoelectrophoresis ofapo VLDL (Fig. 2) and densitometry of apo VLDL and apo HDL subsequent to IEF (Table   I ). In VLDL and HDL, the ratios of normal apo C-III1/normal apo C-III2 and variant apo C-1111/variant apo C-Ill2, respectively, were identical in heterozygous variant carriers. These ratios were similar to those in unaffected family members and PROCAM controls (not shown). However, the concentrations of the normal apo C-III isoforms were increased compared with the respective variant apo C-Ill isoproteins, namely by factors of 7.5 in VLDL and 4 in HDL (Table I ). In desialyated apo C-Ill obtained by neuraminidase treatment the ratios of normal apo C-Ill/variant apo C-Ill were 6.5 in VLDL and 4 in HDL. When density gradient ultracentrifugation was used, we observed that at densities > 1.15 g/ml variant apo C-III but no normal apo C-Ill was detectable (Fig. 3) . Lipid values and apolipoprotein concentrations. A family study showed that the mother of the propositus also presented the apo C-Ill variant. Lipid values and apolipoprotein concentrations of the family members are given in Tables II and III. Plasma concentrations of HDL cholesterol and apo A-I were substantially higher in variant carriers than in unaffected members. They ranged above the 95th percentiles of sex matched PROCAM controls, which in female PROCAM par- ticipants are 83 mg/dl (HDL cholesterol) and 185 mg/dl (apo A-I), respectively (33) . Triglyceride concentrations of the variant carriers were low normal compared with PROCAM controls and unaffected family members (Table III) . The plasma concentrations of apo C-III were low in the variant carriers (6.65±0.78 mg/dl) compared with the unaffected sister of P.Sch. (13.4 mg/dl) as well as with 58 randomly selected women from the PROCAM study (10.2±1.9 mg/dl; P < 0.02, two-tailed t test). None of the variant carriers took drugs that increase plasma HDL cholesterol concentrations (estrogens, fibrates, gi-hydroxy-fl-methylglutaryl CoA reductase inhibitors, ion exchange resins).
Analysis oflipoproteins by density gradient ultracentrifugation and gradient gel electrophoresis. The distribution of lipids and apo A-I within the lipoprotein classes was analyzed after density gradient ultracentrifugation of plasma samples from the variant carriers and the two unaffected family members (Fig. 4) . Marked differences were found in the HDL density Table I The ratios of normal and variant apo C-III isoforms were obtained after integration of densitograms from apo C-Ill separated by IEF of samples from the proposita (P) and her mother (M) who are both heterozygous for the apo C-III variant. Means±SD; n = 3. range. In the two unaffected family members, most ofthe HDL lipids (i.e., 62±4% total cholesterol, 63±4% free cholesterol, 66±5% esterified cholesterol, 57±3% triglycerides, 58±5% phosphatidylcholine, and 73±5% sphingomyeline) and 70±4% of apo A-I were found in the density class of HDL3 (> 1.120 g/ml). In contrast, in the variant carriers only 41±3% total cholesterol, 36±3% free cholesterol, 42±4% esterified cholesterol, 30±3% triglycerides, 45±3% phosphatidylcholine, and 30±4% sphingomyeline and 60±3% of apo A-I were found in HDL3. Compared with unaffected family members the two variant carriers exhibited relatively high concentrations of apo E in both the HDL2 and the HDL3 density ranges. This atypical distribution oflipidsand apo A-I in HDL was accompanied by an atypical particle size distribution. As analyzed by polyacrylamide gradient gel electrophoresis of fractions from density gradient ultracentrifugation (Fig. 4) and by densitometry of HDL particles separated by ultracentrifugation and subsequent gradient gel electrophoresis (Fig. 5) , HDL from the variant carriers mainly consisted of HDL2b. In contrast, control preparations contained mostly HDL3.. In addition, the apo C-IIl variant carriers exhibited an unusually large HDL subclass with a Stokes diameter of 13-18 nm (Fig. 5 ) that corresponds to that described for HDLC (47). Structural analysis ofthe apo C-III variant. For the structural analysis ofthe defect underlying the mutant apo C-III, the most anodic band of the variant apo C-Ill was isolated and digested with trypsin. The resulting chromatogram was grossly identical to that of normal apo C-Ill2, but the retention time of the fraction normally containing T6 was slightly prolonged (peptide T* in Fig. 6 ). TOF-SIMS analysis of this abnormally migrating peptide revealed a molecular mass of 1,141 D, while the normal peptide T6 consisted ofa molecular mass of 898 D. The only possible single nucleotide substitution in APOC3 that can explain both the molecular mass of the T* peptide and the altered pl ofthe variant protein is Lys58 Glu. Sequence analysis revealed a sequence Asp-Tyr-Trp-Ser-Thr-Val-Glu-Asp-Lys (residues 52 -. 60) instead of a normal Asp-Tyr-Trp-Ser-ThrVal-Lys (residues 52 --58), thus verifying the predicted amino acid substitution Lys58 Glu. Analysis offamily membersfor the presence ofthe Lys58
Glu mutation. To verify the Lys58 -. Glu mutation in the proposita and her mother and to exclude its presence in the other two family members, we directly sequenced exon 4 of the apo Values in parentheses give percentiles for HDL cholesterol from sex matched PROCAM controls (33) . The data presented for the proposita represent average values of four analyses performed over a period of 2 yr.
C-III gene subsequent to PCR amplification. This method provides information for both alleles simultaneously. Heterozygosity for an A to G exchange in the first nucleotide of codon 58, which results in a substitution oflysine with glutamic acid, was found in the samples ofthe proposita and her mother but not in those of her father and sister (Fig. 7) . No further deviations from the wild type sequence of apo C-III were observed.
Discussion
women with plasma concentrations of HDL cholesterol and apo A-I that were significantly higher than in unaffected family members. In fact, they were above the 95th percentiles of sex matched controls (33) . (58) found that the apo A-IV polymorphism modulates the HDL cholesterol plasma concentration. The less frequent apo A-IV isoform, which differs from the more frequent by a Gln360 -His exchange (59) , was found associated with higher serum levels of HDL cholesterol. In this report, we describe an apo C-III variant that resulted from the replacement of a lysine in position 58 by a glutamic acid residue. This variant was identified in two (62) , both apo A-I/C-Ill-and apo A-I/C-III/A-IV deficient patients exhibit low plasma concentrations of triglycerides (29, 30) . This has been attributed to the absence ofapo C-Ill as an inhibitor of lipoprotein lipase (19) . (ii) The triglyceride plasma concentration lowering drug MEDICA 16 was shown to exert its effect in rats by enhancing the plasma clearance of chylomicrons. The observed increased fractional catabolic rate results from enhanced liver uptake of chylomicrons. This has been attributed to the 10-fold decrease in the apo C-Ill content of chylomicrons in MEDICA 16-treated animals (63).
(b) Alternatively, the structural defect in apo C-III(Lys.8 Glu) rather than the diminished concentration of apo C-Ill might cause less inhibited clearance of triglyceride rich particles in the heterozygous apo C-Ill variant carriers. The structural requirements for the putative functions of apo C-Ill are, however, poorly understood. Further in vitro and in vivo studies are needed to distinguish between these two possibilities. It is interesting that the substituted amino residue in apo C-
III(Lys58
Glu) is located in the thrombin fragment of apo C-Ill in which the protein's lipid binding properties reside (64 Although apo C-III is little conserved inter species, the positive charge ofamino acid 58 is present in the apo C-III sequences of man, rat and dog (67) . Thus, there is reason to assume that Lys55 occupies a crucial position in apo C-III.
(c) Another observation in support ofa causal relationship between apo C-III(Lys58 -. Glu) and hyperalphalipoproteinemia is our finding that HDL particles in heterozygous individuals were unusual in size, in their apo E content and in the ratio of normal to variant apo C-III. Nondenaturing gradient gel electrophoresis was used to demonstrate that HDL of apo C-III(Lys58 Glu) heterozygotes mainly consisted of HDL2b and a subclass of large HDL particles with a Stokes diameter of 13-18 nm corresponding to the size of HDLC (46) (Figs. 4 and  5 ). These particles were enriched in apo E (Fig. 4) . The concentration ofthe mutant apo C-III was diminished relative to normal apo C-III not only in VLDL but also in HDL. However, with increasing density of HDL the concentration of the variant apo C-III increased relative to that of normal apo C-III and was still present at a density of > 1.15 g/ml where normal apo C-III was undetectable (Fig. 3) . We cannot yet explain the metabolic origin of these unusual HDL subfractions in apo C-III(Lys58 -. Glu) heterozygotes. However, their abundance seems to reflect the high plasma concentration of HDL cholesterol and apo A-I in affected individuals.
Apo C-III(Lys58 --Glu) is the third apo C-III mutant to be described. The two other variants differed from normal apo C-III by their degree of sialyation (14, 26-28). One was oversialyated (14), the other was not sialyated at all because of a Thr --Ala replacement at the glycosylation site (27, 28) . Both ofthese apo C-III variants were not found to be associated with a dyslipoproteinemic phenotype. The observed association of apo C-III(Lys58 --Glu) with apo C-III deficiency and hyperalphalipoproteinemia, however, suggests that the apo C-III gene may affect lipoprotein metabolism profoundly.
